A production line for the manufacturing of this vaccine has been completed by the business. The new production line can produce up to 10 million vaccine doses per month at its maximum capacity. The output will be determined by demand, it was stated.
The firm had said that its Convidencia full cycle manufacturing process will be operational by the end of 2021. CanSino will provide the vaccine’s active ingredient.
The Chinese vaccine’s third round of clinical testing began in Russia in September 2020 and will conclude in September 2021.
Petrovax is a Russian full-cycle medicinal business that is part of the Interros group. It sells both its own unique medications and vaccines developed in collaboration with renowned Russian and international firms. It also produces generic medications. Its production lines are in the Moscow region, with a capacity of 160 million medication doses per year.